28th Jul 2014 10:20
LONDON (Alliance News) - Akers Biosciences Inks feasibility study deal with Japanese technology company Konica Minolta Inc to develop a test for the early detection of cardiac muscle tissue damage, a condition often seen in patients suffering heart attacks.
Akers said that it will study a diagnostic test based on its Particle Immuno Filtration Assay technology, which, if successful, will allow for the rapid detection of biomarkers in a blood sample that can be used to identify this muscle tissue damage.
The tissue damage can occur even at the early stages of a heart attack, Akers said, so early diagnosis could benefit patient treatment.
"Many heart attacks develop slowly; some without obvious symptoms or some with symptoms commonly associated with other conditions such as indigestion, fatigue or stress, said Executive Chairman Raymond Akers Jr in a statement. "Konica Minolta has asked Akers to study a diagnostic test which, if successful, would be the world's first test to diagnose a heart attack in real-time."
Akers will retain all intellectual property rights related to the test being developed.
No financial details of the deal were disclosed.
Shares in Akers were untraded Monday; the stock last closed at 220.00 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L